AtriCure(NASDAQ) ATRC

Market Cap$2.62B

Since IPO (2005)+266%

5 Year-30%

1 Year+49%

1 Month+30%

Premium Feature

Moneyball Superscore

74/100

$53.82

+4.46%

+2.30Today

After hours$53.73-$0.09 (-0.17%)

AtriCure last closing stock price
Metric	Price	Date
Last close	USD 53.73	2026-09-08

AtriCure stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9.83%	USD 48.92	2026-09-01
1 month	+29.81%	USD 41.39	2026-08-07
3 month	+95.31%	USD 27.51	2026-06-10
Year to date	+35.82%	USD 39.56	2025-12-31
1 year	+49.25%	USD 36.00	2025-09-08
3 year	+29.13%	USD 41.61	2023-09-08
5 year	-29.76%	USD 76.50	2021-09-09
Since inception	+265.91%	USD 14.08	2005-08-05

AtriCure Financials at a Glance

Market Cap

$2.62B

Revenue (TTM)

$569.62M

Net Income (TTM)

$10.55M

EPS (TTM)

$0.22

P/E Ratio

237.97

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$53.82

Volume

1,880,277.888

Open

$54.31

Price

$53.82

Volume

1,880,277.888

Open

$54.31

Previous Close

$53.73

Daily Range

$51.74 - $55.72

52-Week Range

$25.36 - $55.72

Estimated Earnings Date

Nov 4, 2026

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$53.82

Volume

1,880,277.888

Open

$54.31

Previous Close

$53.73

Daily Range

$51.74 - $55.72

52-Week Range

$25.36 - $55.72

Estimated Earnings Date

Nov 4, 2026

ATRC News

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

Jonathan PoncianoAug 7, 2026

Page 1

ATRC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AtriCure

AtriCure helps doctors treat common heart rhythm problems with surgery. They make tools that close heart tissue and stop pain. These devices help patients recover from complex heart procedures.

Tools for the Operating Room

Appendage Management: Implantable devices like the AtriClip system used to close a small pouch in the heart called the left atrial appendage; generated $51.6 million in revenue in the second quarter of 2026.
Open Ablation: Devices used during open-heart surgery to treat cardiac tissue with heat or cold; generated $40.9 million in revenue in the second quarter of 2026.
Pain Management: Solutions that freeze nerves to manage pain after chest or heart surgery; generated $27.1 million in revenue in the second quarter of 2026.
Minimally Invasive Ablation: Systems used for standalone procedures to treat atrial fibrillation, a common irregular heart rhythm; generated $6.0 million in revenue in the second quarter of 2026.

Expanding Global Care

Received CE mark approval for the AtriClip FLEX-Mini and PRO-Mini devices in Europe in April 2026.
Completed enrollment for the LeAAPS clinical trial with 6,573 patients across 139 centers globally in July 2025.
Launched the BoxX-NoAF clinical trial to evaluate heart tissue treatment in patients without prior heart rhythm issues.
Expanded training programs to include virtual proctoring, live streaming, and synthetic cadaver models called CADets.

What Sets AtriCure Apart

AtriCure operates in international markets including Germany, France, and Australia using a mix of direct sales and independent distributors. The company focuses on clinical evidence and physician education to increase the adoption of its surgical tools and therapies.

A Snapshot of the Finances

Worldwide revenue reached $153.6 million in the second quarter of 2026, up 12.8% year over year.
Gross margin improved to 77.2% in the second quarter of 2026, up 269 basis points year over year.
Net income was $9.0 million for the quarter ended June 30, 2026, compared to a net loss of $6.2 million in the second quarter of 2025.
Cash and cash equivalents totaled $167.8 million as of June 30, 2026, with an outstanding debt of $61.0 million.

Bottom Line

AtriCure has transitioned from a specialized medical tool maker into a provider of comprehensive therapies for heart rhythm and pain management. Continuous investment in clinical trials and new product launches supports its position in the surgical healthcare market.

AI Generated • Jul 28, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,350

CEO

Michael H. Carrel, MBA

Website

www.atricure.com

Headquarters

Mason, OH 45040, US

ATRC Financials

Key Financial Metrics (TTM)

Gross Margin

76.16%

Operating Margin

2.44%

Net Income Margin

1.85%

Return on Equity

2.14%

Return on Capital

-0.59%

Return on Assets

1.56%

Earnings Yield

0.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.62B

Shares Outstanding

50.87M

Volume

1.88M

Avg. Volume

895.97K

Financials (TTM)

Gross Profit

$433.85M

Operating Income

$13.89M

EBITDA

$27.15M

Operating Cash Flow

$64.94M

Capital Expenditure

-$6.83M

Free Cash Flow

$58.11M

Cash & ST Invst.

$167.79M

Total Debt

$71.05M

AtriCure Performance Analysis

AtriCure annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 330,379,000	20.4%
2023	2023-12-31	USD 399,245,000	20.8%
2024	2024-12-31	USD 465,307,000	16.5%
2025	2025-12-31	USD 534,528,000	14.9%

AtriCure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-1.4%
Q4	2025-12-31	4.6%
Q1	2026-03-31	0.5%
Q2	2026-06-30	8.7%

AtriCure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.02	N/A
2023	2023-12-31	USD -0.66	-35.3%
2024	2024-12-31	USD -0.95	44.8%
2025	2025-12-31	USD -0.24	-74.8%

AtriCure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	95.7%
Q4	2025-12-31	735.7%
Q1	2026-03-31	-93.8%
Q2	2026-06-30	8081.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$153.60M

+12.8%

Gross Profit

$118.63M

+16.9%

Gross Margin

77.23%

N/A

Market Cap

$2.62B

N/A

Market Cap/Employee

$1.94M

N/A

Employees

1,350

N/A

Net Income

$8.96M

+244.7%

EBITDA

$3.18M

+335.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$167.79M

+42.4%

Total Debt

$71.05M

-8.0%

Accounts Receivable

$79.98M

+21.2%

Inventory

$83.93M

+9.9%

Long Term Debt

$71.05M

-4.4%

Short Term Debt

$0.00

-100.0%

Return on Assets

1.56%

N/A

Return on Invested Capital

2.34%

N/A

Free Cash Flow

$18.43M

+32.0%

Operating Cash Flow

$22.19M

+2.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SEMSelect Medical Holdings Corporation

SEMSelect Medical Holdings Corporation$16.51-0.09%

NVCRNovocure Ltd

NVCRNovocure Ltd$16.85-6.08%

LMATLeMaitre Vascular, Inc.

LMATLeMaitre Vascular, Inc.$79.59-1.34%

IMCRImmunocore Holdings plc

IMCRImmunocore Holdings plc$35.36-2.13%

BLFSBioLife Solutions, Inc.

BLFSBioLife Solutions, Inc.$35.38+0.37%

KMTSKestra Medical Technologies, Ltd.

KMTSKestra Medical Technologies, Ltd.$25.64+0.37%

XERSXeris Biopharma Holdings, Inc.

XERSXeris Biopharma Holdings, Inc.$8.48-0.59%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$104.47+0.09%

NVDANvidia

NVDANvidia$225.73-0.02%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.28-0.01%

NOKNokia

NOKNokia$10.65+0.06%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$153.47+0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.87+0.08%

NUNu Holdings

NUNu Holdings$15.33-0.00%

Questions About ATRC

What is the current price of AtriCure?

AtriCure is trading at $53.73 per share.

What is the 52-week range for AtriCure?

Over the past 52 weeks, AtriCure has traded between $25.36 and $55.72.

How much debt does AtriCure have?

As of the most recent reporting period, AtriCure reported total debt of $74.22M.

How much cash does AtriCure have on hand?

AtriCure reported $167.79M in cash and cash equivalents in its most recent financial results.

What is AtriCure’s dividend yield?

AtriCure does not currently have a dividend yield.

AtriCure(NASDAQ) ATRC

AtriCure Financials at a Glance

ATRC News

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

AtriCure (ATRC) Q2 Revenue Jumps 17%

Why Chefs' Warehouse, SMART Global Holdings, and AtriCure Jumped Today

Here's Why ArtiCure, Inc. Is Up Double-Digits Today

Why AtriCure, Inc. Shares Surged

ATRC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About AtriCure

Tools for the Operating Room

Expanding Global Care

What Sets AtriCure Apart

A Snapshot of the Finances

Bottom Line

ATRC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

AtriCure Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ATRC

What is the current price of AtriCure?

What is the 52-week range for AtriCure?

How much debt does AtriCure have?

How much cash does AtriCure have on hand?

What is AtriCure’s dividend yield?

Premium Investing Services